Introduction
Neuroblastoma is the second most common solid malignancy of childhood (after CNS tumors) and the most frequently diagnosed neoplasm during infancy. 1 Almost half of all neuroblastomas are currently classified as high risk. For these high-risk neuroblastoma patients, the use of intensive multimodal therapy with autologous hematopoietic stem cell rescue in consolidation has modestly improved the outcome, but their long-term overall survival remains unsatisfactory (less than 40%). Moreover, no efficient curative option can be currently proposed for refractory/ relapsed high-risk neuroblastomas after completion of conventional treatment. Therefore, new strategies for consolidation and minimal residual disease (MRD) therapy are urgently needed.
Data from the European Group for Blood and Marrow Transplantation (EBMT) activity survey [2] [3] [4] [5] [6] [7] and from the Accreditation Subcommittee of the EBMT classifying hematopoietic SCT (HSCT) procedures according to prevailing clinical practice 8 suggest that there is consensus on autologous HSCT as an indication for high-risk neuroblastoma with a continuous increase in these transplants in Europe. The first allogeneic transplants for neuroblastoma were reported in the 1980s and the early 1990s with a decline thereafter. In recent years, the number of allogeneic HSCT (allo-HSCT) is increasing again (Table 1) , but the proportion of allo-HSCT remains low, reflecting the experimental status of the procedure. Nevertheless, in 2007, neuroblastoma is the first indication of allo-HSCT for solid tumors.
In this brief review of allo-HSCT for high-risk neuroblastoma, we (1) review results and conclusions of conventional (following myeloablative conditioning regimen) allo-HSCT, (2) summarize the preliminary results of reduced-intensity conditioning (RIC) allo-HSCT and (3) mention a small number of haplo-HSCT. We then discuss two main strategies of allo-HSCT currently proposed for high-risk neuroblastoma: allo-HSCT in newly diagnosed patients (combined or not with auto-HSCT) or allo-HSCT as a salvage therapeutic option in relapsed high-risk neuroblastomas after completion of multilineage conventional treatment.
Conventional allo-HSCT
In the early 1990s, European, US and Japanese groups studied allo-HSCT as an alternative to auto-HSCT in advanced neuroblastoma. It can be noted that allo-HSCT was used primarily when autologous BM had not been cleared of tumor or was impossible to harvest, but not really in an attempt to harness an immunotherapeutic effect. A few allogeneic BM transplants with conventional myeloablative conditioning regimens based mainly on melphalan, TBI and etoposide were performed. Data on approximately 50 patients have been published in retrospective case control studies and case reports (Table 2) .
Two major United States and European studies matching allo-HSCT patients vs patient rescued by auto-HSCT showed no significant difference in overall survival, PFS and, contrary to what would be expected, TRM between these two groups. No beneficial antitumor effect of conventional allo-transplantation was demonstrated. Even if GVHD and graft-vs-tumor (GvT) effect are not necessarily linked, one should note that only 50% of allografted patients of both studies developed GVHD, which were mostly mild to moderate. 9, 10 Both studies provided the same conclusion: allo-BMT following myeloablative therapy appears to be equivalent to auto-BMT for high-risk neuroblastoma. Although the interpretation of these results must be done with caution they were retrospective, nonrandomized comparison trials with probable bias in patient's selection (one could expect that the more unfavorable patients were in the allo-BMT group).
More recently, a Japanese team published its experience comparing conventional matched sibling allo-BMT following myeloablative conditioning regimen to reduced-intensity allo-BMT in children with different solid tumors performed between 1994 and 2005. 11 There were five neuroblastoma patients in the conventional/myeloablative conditioning group; however, the paper focuses on the incidences of acute GVHD and details concerning the outcome of neuroblastoma patients were not provided.
Nevertheless, in Europe and United States, allo-HSCT following myeloablative therapy has finally, and maybe too hastily, been largely abandoned in neuroblastoma treatment for more than 10 years.
RIC allo-HSCT
Interest was renewed at the beginning of this century with the first successful reports of RIC transplants in solid tumors, and with some promising experimental studies that have proved a measurable antitumor immune response against neuroblastoma. 12, 13 In the allogeneic setting, the biological targets of the GvT effect are unknown and it has been believed that the GvT effect is questionable in neuroblastoma. Although primary neuroblastoma cells may lack high-level expression of MHC class 1 and class 2 antigens, they should still be good target cells for a cellular immune response given that there is upregulation of both classes of MHC molecules after conventional therapy and after exposure to proinflammatory cytokines. mHA may also be a possible target.
To our knowledge, data on 21 patients with high-risk neuroblastoma who have had allo-HSCT after RIC have been reported (Table 2) .
Two case reports showed evidence of graft-vs-neuroblastoma effect, which was confirmed by the disappearance or decrease of blood and BM MRD and metaiodobenzylguanidine (MIBG) spots after the induction of acute GVHD by withdrawal of immunosuppressive drugs or donor lymphocyte infusion. In both cases, the control of GVHD by immunosuppressive drugs resulted in the reappearance of neuroblastoma. 14, 15 A new approach of the RIC regimen followed by unrelated cord blood transplantation was recently proposed by Del Toro et al. 16, 17 First, they demonstrated that using a fludarabine, BU and antithymocyte globulinbased RIC regimen followed by unrelated cord blood transplant-was well tolerated and resulted in rapid neutrophil and platelet recovery and a greater than 50% stable mixed donor chimerism in children with different diseases. Four patients with neuroblastoma entered this pilot study and detailed data on two of them are available (Table 2) . Second, in a prospective study, they investigated the feasibility of auto-HSCT combined with reduced intensity allo-HSCT to confer a durable GvT immunity with limited procedure-related toxicity. Patients with at least a PR were eligible for consolidation and withdrew prior to allo-HSCT when progressed after auto-HSCT. Once again, siblings and UCB units were considered as donor sources. Time to allo-HSCT after auto-HSCT was o100 days (67-93 days). Four of five patients had some evidence of GVHD. The maximal grade was acute grade III skin and gut GVHD (two patients). One patient had chronic liver GVHD. All five patients were alive, with no evidence of disease, with median time from diagnosis of 41 m (26-50 m). 18 In France, four patients were recently treated according to a protocol on the basis of fludarabine, BU and antilymphocyte serum (ALS) RIC. All received high-dose chemotherapy with auto-HSCT as first-line treatment. The first had matched unrelated donor PBSC transplantation in the first bone and BM relapse after auto-HSCT. He had no evidence of GVHD and died of progressive disease at day þ 95 after allo-HSCT. The second patient had sibling cord blood transplant 5 months after auto-HSCT. Following allo-HSCT, he still had persistent disease and received additional treatment ( 131 I-MIBG and retinoic acid), and so the impact of allo-HSCT on the disease is difficult to assess. Nevertheless, 30 months after allo-HSCT, he is still in remission. In patients 3 and 4, a graft-vs-neuroblastoma effect could be observed. The third patient was clearly not responding to any standard treatment with persistent bone (MIBG) and BM MRD after auto-HSCT. He had HLAidentical sibling BM transplant. As no GVHD occurred at day þ 40 and the number of tyrosine hydroxylase transcripts in the BM had significantly increased, donor lymphocyte infusion was performed at day þ 45 and at day þ 75. It resulted at day þ 90 in a flare of acute grade III hepatic GVHD and a concomitant decrease (2 log) of BM MRD and MIBG spots. Unfortunately, control of GVHD resulted in the reappearance of neuroblastoma and patient died of progressive disease at day þ 130. The fourth patient was in PR (bone MIBG-scan hot spots were still present and BM MRD was detected) after auto-HSCT. He had matched allo-BMT 1 year after auto-HSCT. On day þ 60, as he still had two MIBG-scan hot spots present and no GVHD, immunosupressive treatment was stopped and donor lymphocytes infusion was performed. As there was no clinical or biological evidence of GVHD, donor lymphocyte infusion was repeated on days þ 120, þ 210, þ 300 and 390. After 38 months, he has normal MIBG scan, no blood and no medullar MRD detectable and no GVHD. He is clinically in good strength without any treatment, and has normal school and sport activity.
Nine of the 14 reported patients for whom data are available are alive. TRM was not considered to be exclusive despite some documented GvT effects.
Haplo-HSCT
As far as haplo-HSCT in neuroblastoma is concerned, published experience is limited. Four patients with relapsed metastatic neuroblastomas were reported by Lang et al. 19 This pilot study evaluated the feasibility and toxicity of transplantation of haploidentical T-and B-cell depleted grafts with high numbers of natural killer cells after a melphalan-based RIC. Hematopoietic recovery was rapid. No TRM and only low toxicity occurred. Analysis of posttransplant natural killer cell function revealed low cytotoxic activity against neuroblastoma targets. The authors concluded on the feasibility and low toxicity of this approach even in intensively pre-treated patients with neuroblastoma.
In 2003, Inoue et al. 20 described the outcome of a boy with refractory advanced neuroblastoma who received CD34-positive HLA haploidentical BMT after myeloablative (TBI, thiotepa, etoposide) conditioning. He had residual disease after the first megatherapy followed by autologous CD34 þ BM cell rescue. Allo-HSCT was decided because autologous hematopoietic stem cells for the second graft could not be harvested. He developed grade I acute skin GVHD but had no symptoms of chronic GVHD or any other complications. Residual disease was persistent following the transplant and the patient received additional conventional dose chemotherapy, which did not influence the residual disease. Two years after interruption of all curative therapy residual disease had disappeared completely. The patient has been in a good state of health for more than 4 years after the second transplant, without any sign of relapse. The authors stressed the possibility of a GvT effect against neuroblastoma by HLA-mismatched allo-HSCT.
Discussion and perspectives
Auto-HSCT allows chemotherapy dose intensification beyond marrow tolerance in patients with high-risk neuroblasoma. The first allo-HSCT in the 1990s allowed the same therapeutic approach of dose escalation in patients who had no autologous stem cells available. New concepts of allo-HSCT for neuroblastoma and other solid tumors do not rely on escalation of chemotherapy intensity and tumor load reduction but rather on a GvT effect. At this point, this is still an investigational and unusual application of allogeneic transplant, with 78 neuroblastoma patients reported to the EBMT activity survey from 2002 to 2007. In 2006, the Accreditation Subcommittee of the EBMT classified HSCT procedures according to prevailing clinical practice in Europe and categorized allo-HSCT for high-risk neuroblastoma as a 'clinical option' (with sibling donor) or 'developmental' (with well-matched unrelated donor). 8 It means that allo-HSCT is a valuable option for individual patients, but that for groups of patients the value of allo-HSCT needs further evaluation within the framework of a clinical protocol. However, research into this experimental approach to HSCT in neuroblastoma is ongoing and some questions remain unresolved.
The need for an acceptable donor and the risk of secondary long-term complications weigh heavily on the decision to include allo-HSCT in the therapeutic program in children with high-risk neuroblastoma.
The long-term late effects of allo-HSCT procedure are of crucial importance in the pediatric setting (especially in small children who are more susceptible to such complications because of their developing tissues). These children have 60-70 life years remaining after allo-HSCT and are at risk for significant long-term late effects of myeloablative conditioning (growth retardation, gonad failure and infertility, impairment of intellectual ability, secondary malignancies and secondary MDS). We hypothesize that RIC will decrease the long-term late effects in children. However, the primary concept of RIC was to reduce transplant-related toxicity, and its impact on long-term late effects is still unknown. Recently, a prospective registrybased study of RIC in children has been initiated on behalf of the Pediatric Diseases and Late Effects Working Parties of the EBMT to report early and late complications in children who received an RIC.
Although for many years HLA-matched siblings or unrelated HLA-matched BM donors were the only types of donor routinely employed, more recently alternative hematopoietic stem cell sources (matched unrelated volunteers, unrelated umbilical cord blood and full-haplotypemismatched family members) are being largely used. In pediatric solid tumors, results from Del Toro et al. [16] [17] [18] suggest that unrelated cord blood can be used successfully as a stem cell source following RIC. Although one of the limitations of cord blood transplantation is a significantly reduced cell dose that results in delayed time to myeloid engraftment, its use is optimal in small children (more neuroblastomas occur in low-body-weight children), where a high cell dose per kilogram body weight could be obtained. However, another limitation of cord blood transplantation is the impossibility to administer donor lymphocyte infusions as potential adoptive cellular immunotherapy for disease recurrence.
It is also unclear at what point in the disease course allo-HSCT should be incorporated. Two trends can be observed in the reviewed data: some teams have used allo-HSCT in children with refractory or progressive disease and significant tumor burden and other teams have used allo-HSCT in children with CR, PR or MRD, which was earlier in their disease process. In France, a prospective national pediatric study is now open on behalf of the Socie´teF ranc¸aise de Greffe de Moelle et de The´rapie Cellulaire. The goal of this study is to evaluate the feasibility of allo-HSCT following fludarabine (180 mg/m 2 ), BU (8.8 mg/m 2 ) and ALS (2.5 mg/kg) RIC in children with solid tumors not responding to standard multilineage curative therapy (remaining unresponsive to the reference strategies according to French best practices in pediatrics). HLA-identical donor or one Ag mismatch sibling donor, 10 out of 10 phenoidentical donor or compatible cord blood donor are eligible. Post-transplant immunosuppression is based on CsA alone. An alternative option is on the basis of the hypothesis that immunological effects of allo-HSCT will quite likely be of most benefit in children with malignancies earlier in their disease process, particularly in children obtaining a complete or partial response prior to allo-HSCT. Such an approach is proposed by the Children's Hospital of New York Presbyterian team with sequential auto-HSCT/RIC allo-HSCT for consolidation in newly diagnosed patients. 18 In conclusion, early studies of allo-HSCT in children with high-risk neuroblastoma suggest that this is a feasible approach that may improve the outcome in this deadly disease. Although there are a limited number of reviewed cases, knowledge of these data provides a basis for decision-making in future studies design. Not only in the subset of patients for whom dose escalation strategies appear to be failing but also for newly diagnosed patients, there is a need to develop newer strategies based on innovative, immunobiological concepts.
